Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-09-22

AUTHORS

Tsuyoshi Nozue, Hiroaki Hattori, Kazuyuki Ogawa, Takeshi Kujiraoka, Tadao Iwasaki, Tsutomu Hirano, Ichiro Michishita

ABSTRACT

BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05); small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311. More... »

PAGES

165

References to SciGraph publications

  • 2016-02-19. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese in JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8

    DOI

    http://dx.doi.org/10.1186/s12944-016-0339-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1046753598

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/27658826


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Biochemistry and Metabolomics", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.417368.f", 
              "name": [
                "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nozue", 
            "givenName": "Tsuyoshi", 
            "id": "sg:person.01033145125.12", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hattori", 
            "givenName": "Hiroaki", 
            "id": "sg:person.01306227053.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306227053.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ogawa", 
            "givenName": "Kazuyuki", 
            "id": "sg:person.01022006542.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022006542.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kujiraoka", 
            "givenName": "Takeshi", 
            "id": "sg:person.01130141300.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130141300.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iwasaki", 
            "givenName": "Tadao", 
            "id": "sg:person.0751577337.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751577337.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410714.7", 
              "name": [
                "Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hirano", 
            "givenName": "Tsutomu", 
            "id": "sg:person.016274235662.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016274235662.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.417368.f", 
              "name": [
                "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Michishita", 
            "givenName": "Ichiro", 
            "id": "sg:person.0732262025.70", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s40618-016-0433-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052469678", 
              "https://doi.org/10.1007/s40618-016-0433-9"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2016-09-22", 
        "datePublishedReg": "2016-09-22", 
        "description": "BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r\u2009=\u20090.195, p\u2009=\u20090.05); small, dense LDL (r\u2009=\u20090.336, p\u2009=\u20090.0006); and oxidized LDL (r\u2009=\u20090.268, p\u2009=\u20090.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (\u03b2\u2009=\u20090.235, p\u2009=\u20090.01); small, dense LDL (\u03b2\u2009=\u20090.143, p\u2009=\u20090.03); and oxidized LDL (\u03b2\u2009=\u20090.268, p\u2009=\u20090.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12944-016-0339-8", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1031029", 
            "issn": [
              "1476-511X"
            ], 
            "name": "Lipids in Health and Disease", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "15"
          }
        ], 
        "keywords": [
          "proprotein convertase subtilisin/kexin type 9", 
          "coronary artery disease", 
          "convertase subtilisin/kexin type 9", 
          "subtilisin/kexin type 9", 
          "serum levels", 
          "dense LDL", 
          "artery disease", 
          "PCSK9 levels", 
          "atherogenic lipoproteins", 
          "serum low-density lipoprotein cholesterol levels", 
          "type 9", 
          "low-density lipoprotein cholesterol levels", 
          "serum proprotein convertase subtilisin/kexin type 9", 
          "lipid-lowering therapy", 
          "metabolic risk factors", 
          "lipoprotein cholesterol levels", 
          "Clinical Trials Registry", 
          "body mass index", 
          "levels of triglycerides", 
          "multivariate regression analysis", 
          "atherosclerotic status", 
          "MethodsSerum levels", 
          "Trials Registry", 
          "mass index", 
          "cholesterol levels", 
          "risk factors", 
          "apolipoprotein B", 
          "patients", 
          "LDL", 
          "lipoprotein", 
          "significant predictors", 
          "regression analysis", 
          "disease", 
          "key regulator", 
          "levels", 
          "registry", 
          "therapy", 
          "triglycerides", 
          "insulin", 
          "trials", 
          "predictors", 
          "glucose", 
          "correlation", 
          "status", 
          "index", 
          "factors", 
          "study", 
          "role", 
          "regulator", 
          "purpose", 
          "analysis", 
          "ID", 
          "interaction"
        ], 
        "name": "Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease", 
        "pagination": "165", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1046753598"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12944-016-0339-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "27658826"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12944-016-0339-8", 
          "https://app.dimensions.ai/details/publication/pub.1046753598"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-06-01T22:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_700.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12944-016-0339-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    166 TRIPLES      22 PREDICATES      80 URIs      71 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12944-016-0339-8 schema:about anzsrc-for:11
    2 anzsrc-for:1101
    3 schema:author N76e1037a55314945807913066a84e633
    4 schema:citation sg:pub.10.1007/s40618-016-0433-9
    5 schema:datePublished 2016-09-22
    6 schema:datePublishedReg 2016-09-22
    7 schema:description BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05); small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311.
    8 schema:genre article
    9 schema:inLanguage en
    10 schema:isAccessibleForFree true
    11 schema:isPartOf N6e11c5764dac42f7a9e6088e54e1ee62
    12 Nb4839c368492474f9faf1b641c43dcf9
    13 sg:journal.1031029
    14 schema:keywords Clinical Trials Registry
    15 ID
    16 LDL
    17 MethodsSerum levels
    18 PCSK9 levels
    19 Trials Registry
    20 analysis
    21 apolipoprotein B
    22 artery disease
    23 atherogenic lipoproteins
    24 atherosclerotic status
    25 body mass index
    26 cholesterol levels
    27 convertase subtilisin/kexin type 9
    28 coronary artery disease
    29 correlation
    30 dense LDL
    31 disease
    32 factors
    33 glucose
    34 index
    35 insulin
    36 interaction
    37 key regulator
    38 levels
    39 levels of triglycerides
    40 lipid-lowering therapy
    41 lipoprotein
    42 lipoprotein cholesterol levels
    43 low-density lipoprotein cholesterol levels
    44 mass index
    45 metabolic risk factors
    46 multivariate regression analysis
    47 patients
    48 predictors
    49 proprotein convertase subtilisin/kexin type 9
    50 purpose
    51 registry
    52 regression analysis
    53 regulator
    54 risk factors
    55 role
    56 serum levels
    57 serum low-density lipoprotein cholesterol levels
    58 serum proprotein convertase subtilisin/kexin type 9
    59 significant predictors
    60 status
    61 study
    62 subtilisin/kexin type 9
    63 therapy
    64 trials
    65 triglycerides
    66 type 9
    67 schema:name Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    68 schema:pagination 165
    69 schema:productId N05c59aa88e8a45b4b13d0b4ae6322558
    70 N108920e109fa466d84de33efbc8d5e5a
    71 N6cfec691317343d4a84619a8b6f9d7e2
    72 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046753598
    73 https://doi.org/10.1186/s12944-016-0339-8
    74 schema:sdDatePublished 2022-06-01T22:17
    75 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    76 schema:sdPublisher N9c800c470f2847cd833715b9fe39e8c8
    77 schema:url https://doi.org/10.1186/s12944-016-0339-8
    78 sgo:license sg:explorer/license/
    79 sgo:sdDataset articles
    80 rdf:type schema:ScholarlyArticle
    81 N05c59aa88e8a45b4b13d0b4ae6322558 schema:name pubmed_id
    82 schema:value 27658826
    83 rdf:type schema:PropertyValue
    84 N108920e109fa466d84de33efbc8d5e5a schema:name doi
    85 schema:value 10.1186/s12944-016-0339-8
    86 rdf:type schema:PropertyValue
    87 N2c97f8b18ad84cd0ab234c48d9eeb023 rdf:first sg:person.0732262025.70
    88 rdf:rest rdf:nil
    89 N3e3bf91fee5841a08efa35ea6c42da74 rdf:first sg:person.0751577337.13
    90 rdf:rest N86b6cacb0ef64f5abfbdfea6d623f59f
    91 N48f21151931240bda652ef9c9055888a rdf:first sg:person.01306227053.48
    92 rdf:rest N4a4473e0a1844e1895cb73e028e55938
    93 N4a4473e0a1844e1895cb73e028e55938 rdf:first sg:person.01022006542.43
    94 rdf:rest N740ba76ac76046fe94b90cb4310a70e9
    95 N6cfec691317343d4a84619a8b6f9d7e2 schema:name dimensions_id
    96 schema:value pub.1046753598
    97 rdf:type schema:PropertyValue
    98 N6e11c5764dac42f7a9e6088e54e1ee62 schema:issueNumber 1
    99 rdf:type schema:PublicationIssue
    100 N740ba76ac76046fe94b90cb4310a70e9 rdf:first sg:person.01130141300.55
    101 rdf:rest N3e3bf91fee5841a08efa35ea6c42da74
    102 N76e1037a55314945807913066a84e633 rdf:first sg:person.01033145125.12
    103 rdf:rest N48f21151931240bda652ef9c9055888a
    104 N86b6cacb0ef64f5abfbdfea6d623f59f rdf:first sg:person.016274235662.39
    105 rdf:rest N2c97f8b18ad84cd0ab234c48d9eeb023
    106 N9c800c470f2847cd833715b9fe39e8c8 schema:name Springer Nature - SN SciGraph project
    107 rdf:type schema:Organization
    108 Nb4839c368492474f9faf1b641c43dcf9 schema:volumeNumber 15
    109 rdf:type schema:PublicationVolume
    110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    111 schema:name Medical and Health Sciences
    112 rdf:type schema:DefinedTerm
    113 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
    114 schema:name Medical Biochemistry and Metabolomics
    115 rdf:type schema:DefinedTerm
    116 sg:journal.1031029 schema:issn 1476-511X
    117 schema:name Lipids in Health and Disease
    118 schema:publisher Springer Nature
    119 rdf:type schema:Periodical
    120 sg:person.01022006542.43 schema:affiliation grid-institutes:grid.410848.1
    121 schema:familyName Ogawa
    122 schema:givenName Kazuyuki
    123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022006542.43
    124 rdf:type schema:Person
    125 sg:person.01033145125.12 schema:affiliation grid-institutes:grid.417368.f
    126 schema:familyName Nozue
    127 schema:givenName Tsuyoshi
    128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12
    129 rdf:type schema:Person
    130 sg:person.01130141300.55 schema:affiliation grid-institutes:grid.410848.1
    131 schema:familyName Kujiraoka
    132 schema:givenName Takeshi
    133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130141300.55
    134 rdf:type schema:Person
    135 sg:person.01306227053.48 schema:affiliation grid-institutes:grid.410848.1
    136 schema:familyName Hattori
    137 schema:givenName Hiroaki
    138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306227053.48
    139 rdf:type schema:Person
    140 sg:person.016274235662.39 schema:affiliation grid-institutes:grid.410714.7
    141 schema:familyName Hirano
    142 schema:givenName Tsutomu
    143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016274235662.39
    144 rdf:type schema:Person
    145 sg:person.0732262025.70 schema:affiliation grid-institutes:grid.417368.f
    146 schema:familyName Michishita
    147 schema:givenName Ichiro
    148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70
    149 rdf:type schema:Person
    150 sg:person.0751577337.13 schema:affiliation grid-institutes:grid.410848.1
    151 schema:familyName Iwasaki
    152 schema:givenName Tadao
    153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751577337.13
    154 rdf:type schema:Person
    155 sg:pub.10.1007/s40618-016-0433-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052469678
    156 https://doi.org/10.1007/s40618-016-0433-9
    157 rdf:type schema:CreativeWork
    158 grid-institutes:grid.410714.7 schema:alternateName Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan
    159 schema:name Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan
    160 rdf:type schema:Organization
    161 grid-institutes:grid.410848.1 schema:alternateName Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan
    162 schema:name Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan
    163 rdf:type schema:Organization
    164 grid-institutes:grid.417368.f schema:alternateName Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan
    165 schema:name Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan
    166 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...